The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.

ESMO open. 2017;2(3):e000219

Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(8):1148-55

Bugés C, Carcereny E, Moran T, Cardona AF, Reguart N, Capdevila L, Cros S, Rosell R

Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.

Clinical lung cancer. 2015;16(2):e1-3

Ji Y, Zhang Z, Nie K, Lan K, Geng C, Liu S, Zhang L, Zhang Z, Sun L, Zou X

Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.

Chinese medical journal. 2014;127(8):1600

Rothenstein JM, Letarte N

Managing treatment-related adverse events associated with Alk inhibitors.

Current oncology (Toronto, Ont.). 2014;21(1):19-26

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

The New England journal of medicine. 2013;368(25):2385-94

Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(1):e15-7